Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials-Reference-Cited by-同舟云学术

Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials

Published:2019-03-22 Issue:1 Volume:181 Page:196-197
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Blauvelt A.^ORCID,Rosmarin D.^ORCID,Bieber T.,Simpson E.L.,Bagel J.,Worm M.,Deleuran M.^ORCID,Katoh N.,Kawashima M.,Shumel B.,Chen Z.,Rossi A.B.,Hultsch T.,Ardeleanu M.

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.17703

Reference8 articles.

1. Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas

2. The role of Malassezia in atopic dermatitis affecting the head and neck of adults

3. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes

4. Commonality of the IL-4/IL-13 pathway in atopic diseases

5. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Eczema Area and Severity Index: An update of progress and challenges in its measurement of atopic dermatitis after 20 years of use;Journal of the European Academy of Dermatology and Venereology;2024-08-19

2. Effectiveness of dupilumab in atopic dermatitis on the head and neck: a single‐center study on 553 patients;International Journal of Dermatology;2024-06-14

3. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial;Journal of the American Academy of Dermatology;2024-06

4. Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch;Dermatology and Therapy;2024-05-22

5. Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis;Dermatology and Therapy;2024-05